A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects With Pulmonary Tuberculosis

Trial Profile

A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects With Pulmonary Tuberculosis

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Isoniazid (Primary) ; Ethambutol; Pyrazinamide; Rifampicin
  • Indications Liver injury; Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Sponsors Orient Pharma
  • Most Recent Events

    • 02 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 02 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Apr 2017, according to ClinicalTrials.gov record.
    • 17 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top